IL33 and neoplasm: In orthotopic but not subcutaneous mouse models, IL-33 activates ILC2s, which in turn produce CCL5 to recruit CD103+ cDC1s to the TME which then prime and activate CD8 T cells to infiltrate the tumor and exert an anti-tumor immune response (144).